CKD Treatment: Addressing Kidney and Cardiometabolic Outcomes Part 4: Mineralocorticoid Receptor Antagonists
A new non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, is FDA-approved for kidney and heart protection in patients with type 2 diabetes. In this module, we will be introducing the different MRAs that are commercially available and discussing the evidence to support their use in patients with kidney disease. This will include a focus on criteria for use of finerenone in our patients with type 2 diabetes, and the patient-specific considerations of when to use this medication.
By the end of this module, learners will be able to:
- Summarize the evidence to support use of finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), compared to other steroidal MRAs for slowing CKD progression, reducing albuminuria and cardiovascular risk.
- Determine the goals of therapy for critical effectiveness and safety endpoints for use of MRAs in patients with kidney disease
- Design care plans to facilitate pharmacoequity for the use of GLP4RAs by ensuring access and optimal use across populations
- Using a patient case:
- Apply guideline-directed medication therapy (or evidence-based medication practice) for MRA use to reduce CKD progression, albuminuria and cardiovascular risk
- Create a monitoring plan for MRAs safety and effectiveness in a patient with CKD
- Describe the risk of hyperkalemia with MRAs and finerenone in patients with CKD stages 4-5 and apply strategies to reduce hyperkalemia if it occurs
Time: 30 minutes
Disclosure
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Katie Cardone, PharmD, BCACP, FNKF, FASN, FCCP - Grants/Research Support [Merck & Co], Consultant [Vifor, Otsuka], Honorarium [Pharmacy Times]
- Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK, Wolters-Kluwer (Lexicorp)]
- Wendy St. Peter, FCCP, FASN, FNKF - Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for .5 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded .5 contact hours of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for .5 contact hours. UAN: JA4008105-9999-23-031-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
